OPRM1 and ABCB1 Polymorphisms and Their Effect on Postoperative Pain Relief With Piritramide

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F15%3A10315870" target="_blank" >RIV/00216208:11110/15:10315870 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064203:_____/15:10315870

Výsledek na webu

<a href="http://www.biomed.cas.cz/physiolres/pdf/64/64_S521.pdf" target="_blank" >http://www.biomed.cas.cz/physiolres/pdf/64/64_S521.pdf</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

OPRM1 and ABCB1 Polymorphisms and Their Effect on Postoperative Pain Relief With Piritramide

Popis výsledku v původním jazyce

Genetic factors may contribute to the differential response to opioids. The aim of this study was to evaluate the association between polymorphisms of mu 1-opioid receptor gene OPRM1 (rs1799971), and P-glycoprotein transporter gene ABCB1 (rs1045642, rs2032582), and piritramide efficacy under postoperative patient-controlled analgesia (PCA). In 51 patients, OPRM1 variant was associated with decreased efficacy in early postoperative period evidenced by sum of pain intensity difference in the 0-6 h postoperative period (SPID0-6), (F=3.27, p=0.029). Mean (SD) SPID0-6 was observed in the 118AA genotype 22.9 (6.1) mm, which was significantly higher from the 118GG genotype 10.0 (4.4) mm, p=0.006. The lowest cumulative dose was recorded in 118AA genotype 19.1(9.8) mg, which was significantly less than in the 118GG genotype group 36.6 (6.1) mg, p=0.017. Opioid-induced adverse effects were observed in 11, 30, and 100 % of patients in 118AA, 118AG, and 118GG genotype groups, respectively (p<0.05

Název v anglickém jazyce

OPRM1 and ABCB1 Polymorphisms and Their Effect on Postoperative Pain Relief With Piritramide

Popis výsledku anglicky

Genetic factors may contribute to the differential response to opioids. The aim of this study was to evaluate the association between polymorphisms of mu 1-opioid receptor gene OPRM1 (rs1799971), and P-glycoprotein transporter gene ABCB1 (rs1045642, rs2032582), and piritramide efficacy under postoperative patient-controlled analgesia (PCA). In 51 patients, OPRM1 variant was associated with decreased efficacy in early postoperative period evidenced by sum of pain intensity difference in the 0-6 h postoperative period (SPID0-6), (F=3.27, p=0.029). Mean (SD) SPID0-6 was observed in the 118AA genotype 22.9 (6.1) mm, which was significantly higher from the 118GG genotype 10.0 (4.4) mm, p=0.006. The lowest cumulative dose was recorded in 118AA genotype 19.1(9.8) mg, which was significantly less than in the 118GG genotype group 36.6 (6.1) mg, p=0.017. Opioid-induced adverse effects were observed in 11, 30, and 100 % of patients in 118AA, 118AG, and 118GG genotype groups, respectively (p<0.05

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FR - Farmakologie a lékárnická chemie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Physiological Research

ISSN

0862-8408

e-ISSN

—

Svazek periodika

64

Číslo periodika v rámci svazku

Suppl. 4

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

7

Strana od-do

"S521"-"S527"

Kód UT WoS článku

000367548600011

EID výsledku v databázi Scopus

2-s2.0-84952647779